Titre
Management of Fulminant Multiple Sclerosis With Rituximab: A Case Report.
Type
article
Institution
UNIL/CHUV/Unisanté + institutions partenaires
Périodique
Auteur(s)
Parfenov, V.
Auteure/Auteur
Du Pasquier, R.
Auteure/Auteur
Schluep, M.
Auteure/Auteur
Liens vers les personnes
Liens vers les unités
ISSN
2331-2637
Statut éditorial
Publié
Date de publication
2015
Volume
19
Numéro
6
Première page
155
Dernière page/numéro d’article
157
Peer-reviewed
Oui
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish
Résumé
INTRODUCTION: Malignant variant is a rare subtype of multiple sclerosis (MS) that is rapidly progressive and may lead to significant disability or even death. No consensus exists on best management of this disorder, although corticosteroids and plasmapheresis are commonly used in the acute phase, followed either by MS-specific disease-modifying therapy or an immunosuppressant.
CASE REPORT: The patient is a 30-year-old man with relapsing-remitting MS previously well controlled with natalizumab, who has developed fulminant disease activity upon natalizumab cessation. In the acute phase, patient had a suboptimal response to multiple corticosteroid treatments but responded very well to plasmapheresis. Patient continued to have worsening disease activity despite fingolimod treatment. Disease control has been eventually achieved by switching to rituximab.
CONCLUSION: Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis.
CASE REPORT: The patient is a 30-year-old man with relapsing-remitting MS previously well controlled with natalizumab, who has developed fulminant disease activity upon natalizumab cessation. In the acute phase, patient had a suboptimal response to multiple corticosteroid treatments but responded very well to plasmapheresis. Patient continued to have worsening disease activity despite fingolimod treatment. Disease control has been eventually achieved by switching to rituximab.
CONCLUSION: Rituximab treatment should be considered for a patient with fulminant MS who responded well to plasmapheresis.
PID Serval
serval:BIB_7C13D7931E14
PMID
Date de création
2016-02-02T09:38:37.549Z
Date de création dans IRIS
2025-05-20T21:33:08Z